And even the New York Times admitted it. I came across this in researching 
the recent allegations that the Clinton Foundation used an Indian drug 
manufacturer that is prohibited from selling drugs in the US due to its 
known horrific lack of quality. This was from 2007:

Clinton Foundation Announces a Bargain* on Generic AIDS Drugs 

By CELIA W. DUGGER <>MAY 9, 2007 

Former President Bill Clinton announced yesterday that his foundation had 
negotiated deep price reductions for generic versions of costly, 
second-line AIDS 
drugs needed when the original medicines fail, as well as for less toxic, 
easier-to-use first-line medicines combined in a pill that can be taken 
once a day.

Standing next to Thailand 
health minister, Mr. Clinton also forcefully endorsed recent decisions by 
Thailand and Brazil 
to break patents held by American pharmaceutical companies that are 
charging prices Mr. Clinton described as exorbitant, but that drug company 
officials said were reasonable.

“No company will live or die because of high price premiums for AIDS drugs 
in middle-income countries, but patients may,” he said.

The new prices would halve the cost of the drugs for better-off developing 
countries in Latin America and Asia and cut prices by 25 percent in poor 
countries, which were already paying lower prices, the foundation said. The 
second-line medicines will be bought with more than $100 million raised by 
a group of countries led by France. The improved first-line therapies will 
largely be financed by the Global Fund to Fight AIDS, Tuberculosis and 
Malaria and other donors.

Second-line drugs have typically cost about 10 times as much as first-line 
therapies. Costs have ballooned in Brazil and Thailand, which began 
programs to provide universal access to AIDS treatment years before African 
countries did, as patients have developed resistance to generic first-line 
treatments and have moved to brand-name second-line drugs.

The Clinton Foundation’s willingness to buy the generic drugs from the 
Indian manufacturers Cipla and Matrix will give developing countries 
leverage in bargaining with American companies for lower prices on branded 
antiretroviral drugs and may embolden some to follow Brazil and Thailand in 
overriding patents, AIDS activists said.

But developing countries still have reason to worry about retaliation from 
drug companies and trade sanctions by the United States. This year, Abbott 
Laboratories, based in Illinois, withdrew new drugs, including those for 
high blood pressure 
and AIDS, that it had planned to introduce in Thailand until the override 
on Abbott’s patent on the second-line drug, Kaletra.

United States trade officials last week put Thailand on a watch list for 
countries inadequately safeguarding the intellectual property rights of 
American companies, noting the overriding of drug patents.

Tido von Shoen-Angerer, who leads the campaign by Doctors Without Borders 
for access to medicines, said he was unsure whether the recent developments 
would encourage developing countries to exercise their rights under 
international trade rules more freely to make or import generic drugs.

“There’s a strong chilling effect from the U.S. action,” he said.

Drug company officials yesterday strongly defended their policies of 
charging better-off developing countries more for AIDS drugs than they did 
for poor countries, as well as the role of patents, which give inventor 
companies a monopoly on the sale of a drug, in stimulating the development 
of new drugs.

Jennifer Smoter, a spokeswoman for Abbott, said patents were needed “to 
ensure innovation in the future” but declined to respond to Mr. Clinton’s 
comment that “Abbott has been almost alone in its hard-line position here 
over what I consider to be a life and death matter.”

Abbott had been charging $2,200 annually per patient for Kaletra in 
middle-income developing countries, which include India, China, Brazil and 
Ukraine. Last month, it dropped the price to $1,000. The foundation’s new 
price for the generic is $695.

Jeffrey L. Sturchio, a vice president at Merck 
in New Jersey, says his company strives to balance providing the broadest 
possible access to AIDS drugs while maintaining financial incentives to 
attract companies to conduct research and development on new drugs.

Brazil and Thailand have overridden Merck’s patent on the AIDS drug 
efavirenz, an ingredient of the new, improved first-line AIDS therapies. 
Merck had been charging Brazil $577 annually per patient, a price it agreed 
to drop to $400 a year after Brazil said it was considering overriding the 
patent. The Clinton Foundation’s new price for the generic drug is $164.

*Bill Clinton, a former president of the United States and then husband of 
a US Senator from NY, encouraged two foreign governments to break patents 
held by two US companies - because he decided their prices were too high. 
To hell with the precedent set, right?

If elected, Hillary wouldn't wait until she's out of office to be doing 
this shit. It's "America last" with these two. :(

Thanks for being part of "PoliticalForum" at Google Groups.
For options & help see

* Visit our other community at  
* It's active and moderated. Register and vote in our polls. 
* Read the latest breaking news, and more.

You received this message because you are subscribed to the Google Groups 
"PoliticalForum" group.
To unsubscribe from this group and stop receiving emails from it, send an email 
For more options, visit

Reply via email to